抗生素联合日达仙治疗重症肺炎患者的临床疗效观察  

Analysis of Clinical Efficacy of Antibiotics and Zadaxin on Treatment of Patients with Severe Pneumonia

作　　者：隋东江[1] 李伟生[1] 王肇源[1] 王蓉美[1] 

机构地区：[1]中国人民解放军空军总医院干部病房3区,北京100142

出　　处：《河北医学》2013年第4期513-516,共4页Hebei Medicine

摘　　要：目的:评价抗生素联合日达仙治疗重症肺炎患者的疗效和安全性。方法:收集本院120例重症肺炎患者的临床治疗资料,其中68例单独应用头孢哌酮/舒巴坦钠进行治疗,52例应用头孢哌酮/舒巴坦钠联合日达仙治疗。结果:单独应用头孢哌酮/舒巴坦钠与联合应用日达仙治疗重症肺炎的临床有效率分别是85.29%和96.15%,二者相比具有显著性差异(P<0.05);细菌清除率分别为69%和86%,二者相比具有显著性差异(P<0.05);联合应用日达仙治疗能够明显提高铜绿假单胞杆菌的清除率;不良反应发生率为7.0%和5.0%,二者相比没有明显差异(P>0.05)。结论:联合日达仙治疗重症肺炎患者的临床疗效明显优于单纯应用抗生素治疗,是治疗重症肺炎的有效方案。Objective： To evaluate the efficacy and safety of antibiotic and Zadaxin on the treatment of patients with severe pneumonia. Method： Clinical treatment datas of 120 cases of patients with severe pneu- monia have been collected from our hospital . 68 cases were treated alone of cefoperazone / sulbactam , 52 were treated with cefoperazone / sulbactam and zadaxin. Result： Clinical efficiency of alone cefoperazone / sulbactam and cefoperazone / sulbactam combination of zadaxin for treatment of severe pneumonia was re- spectively 85.29% and 96.15% , there＇re the significant difference between two groups （P 〈0.05 ）, and bac- terial clearance rate was respectively 69% and 86%, there＇re significant difference between two groups （ P 〈0.05 ） ; application of cefoperazone / sulbactam combination of Zadaxin can significantly improve the clear- ance of pseudomonas aeruginosa a cell of Bacillus ; adverse reactions of two groups was respectively 7.0% and 5.0% , There＇s no significant difference （ P〉 0.05 }. Conclusion： The clinical efficacy of antibiotic and Zadaxin treatment for patients with severe pneumonia is significantly better than the simple application of an- tibiotic , this an effective programme for the treatment of severe pneumonia.

关 键 词：日达仙 重症肺炎 联合应用 

分 类 号：R563.1[医药卫生—呼吸系统]